| Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020 A Haslam, MS Kim, V Prasad Annals of Oncology 32 (7), 926-932, 2021 | 88 | 2021 |
| The contemporary management of cancers of the sinonasal tract in adults R Thawani, MS Kim, A Arastu, Z Feng, MT West, NF Taflin, KZ Thein, R Li, ... CA: a cancer journal for clinicians 73 (1), 72-112, 2023 | 84 | 2023 |
| Paraganglioma of the head and neck: a review L Sandow, R Thawani, MS Kim, MC Heinrich Endocrine Practice 29 (2), 141-147, 2023 | 46 | 2023 |
| Persistent challenges with treating multiple myeloma early AM Goodman, MS Kim, V Prasad Blood, The Journal of the American Society of Hematology 137 (4), 456-458, 2021 | 24 | 2021 |
| Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 US cancer centers KA David, S Sundaram, SH Kim, R Vaca, Y Lin, S Singer, MK Malecek, ... American journal of hematology 98 (6), 900-912, 2023 | 18 | 2023 |
| Clinical trials portfolio and regulatory history of Idelalisib in indolent non-Hodgkin lymphoma: a systematic review and meta-analysis T Banerjee, MS Kim, A Haslam, V Prasad JAMA Internal Medicine 183 (5), 435-441, 2023 | 15 | 2023 |
| The clinical trials portfolio for on-label and off-label studies of eculizumab MS Kim, V Prasad JAMA internal medicine 180 (2), 315-317, 2020 | 14 | 2020 |
| Pembrolizumab for all MS Kim, V Prasad Journal of Cancer Research and Clinical Oncology 149 (3), 1357-1360, 2023 | 13 | 2023 |
| Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia SES Zoe L Lyski, Myung S Kim, David Xthona Lee, Hans-Peter Raué, Vikram ... Blood Advances 6 (4), 1207-1211, 2022 | 13 | 2022 |
| Overall survival for oncology drugs approved for genomic indications A Haslam, MS Kim, V Prasad European Journal of Cancer 160, 175-179, 2022 | 10 | 2022 |
| Quality of biomarker defined subgroups in FDA approvals of PD‐1/PD‐L1 inhibitors 2014 to 2020 MS Kim, A Xu, A Haslam, V Prasad International journal of cancer 150 (11), 1905-1910, 2022 | 9 | 2022 |
| Comparison of classification of indications for allogeneic and autologous transplant for adults in ASTCT guidelines and evidence available in published literature MS Kim, J Cai, A Maniar, T Kartika, A Haslam, V Prasad JAMA Internal Medicine 182 (1), 76-78, 2022 | 9 | 2022 |
| The frequency of medical reversals in a cross-sectional analysis of high-impact oncology journals, 2009–2018 A Haslam, J Gill, T Crain, D Herrera-Perez, EY Chen, T Hilal, MS Kim, ... BMC cancer 21, 1-9, 2021 | 9 | 2021 |
| Nested and adjacent subgroups in cancer clinical trials: when the best interests of companies and patients diverge MS Kim, V Prasad European Journal of Cancer 155, 163-167, 2021 | 9 | 2021 |
| Approval and coverage of cancer drugs in England, Canada, and the US V Prasad, MS Kim JAMA Internal Medicine 181 (4), 509-510, 2021 | 8 | 2021 |
| US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and … MS Kim, V Prasad Cancer 126 (19), 4270-4272, 2020 | 8 | 2020 |
| Assessment of accuracy of waterfall plot representations of response rates in cancer treatment published in medical journals MS Kim, V Prasad JAMA network open 2 (5), e193981-e193981, 2019 | 8 | 2019 |
| Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study L Samples, J Voutsinas, B Fakhri, S Khajavian, S Spurgeon, D Stephens, ... Blood advances 8 (9), 2085-2093, 2024 | 5 | 2024 |
| Cross-sectional analysis characterizing the use of rank preserving structural failure time in oncology studies: changes to hazard ratio and frequency of inappropriate use V Prasad, MS Kim, A Haslam Trials 24 (1), 373, 2023 | 5 | 2023 |
| EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort P Agrawal, KA David, Z Chen, S Sundaram, SH Kim, R Vaca, Y Lin, ... Leukemia & lymphoma 64 (5), 1026-1034, 2023 | 5 | 2023 |
